Lataa...
Idelalisib induces PUMA-dependent apoptosis in colon cancer cells
Idelalisib, a PI3K inhibitor, specifically targeting p110δ, has been approved for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma. However, the mechanisms of action of idelalisib in colon cancer cells are not well understood. We investigated how idela...
Tallennettuna:
| Julkaisussa: | Oncotarget |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Impact Journals LLC
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5351616/ https://ncbi.nlm.nih.gov/pubmed/28008149 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14043 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|